Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients

Fig. 1

Relationship between PRO-C3, C1M, C3M, C4M and VICM levels at baseline and response. a Biomarker levels at baseline in serum from patients with progressive disease (PD) (n = 41) were compared to levels in patients with complete response (CR), partial response (PR) and stable disease (SD) (CR + PR + SD) (n = 25) with Mann-Whitney test. The black horizontal lines represent the median value of the patients. The reference limits for healthy individuals are illustrated with dotted lines (7.5–16.7 ng/ml, 14.0–35.6 ng/ml, 7–13.4 ng/ml, 14.5–28.3 ng/ml and 1.5–16.3 ng/ml for PRO-C3, C1M, C3M, C4M and VICM, respectively.) Asterisks indicate the following: *, p < 0.05 and **, p < 0.01. b Serum levels were dichotomized by the 75th percentile for PRO-C3, C1M, C3M and C4M (Q4, n = 16) and by the median for VICM (Q3 + Q4, n = 33). Next, quantity of patients achieving disease control (CR + PR + SD) where compared to non-responders (PD) in each group

Back to article page